¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"transport phenomenon"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • cytopathogenic phenomenon
    ¼¼Æ÷º¯¼ºÇö»ó
  • centralization phenomenon
    Áß½ÉÈ­Çö»ó
  • duplication phenomenon
    º¹Á¦Çö»ó
  • delay phenomenon
    Áö¿¬Çö»ó
  • dawn phenomenon
    »õº®Çö»ó, ¿©¸íÇö»ó
  • discontinuity phenomenon
    ºÒ¿¬¼ÓÇö»ó
  • dissociative phenomenon
    ÇØ¸®Çö»ó
  • doll¡¯s head phenomenon
    ÀÎÇü¸Ó¸®Çö»ó
  • entoptic phenomenon
    ³»½ÃÇö»ó
  • entry phenomenon
    ÁøÀÔÇö»ó
  • entry slice phenomenon
    ÁøÀÔÀýÆíÇö»ó
  • escape phenomenon
    ÀÌÅ»Çö»ó
  • gap phenomenon
    °£±ØÇö»ó, Æ´Çö»ó
  • iceberg phenomenon
    ºù»êÇö»ó
  • isomorphic phenomenon
    µ¿ÇüÇö»ó
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • passive transport
    ¼öµ¿¿î¹Ý
  • supersonic transport
    ÃÊÀ½ÆÄ¼ö¼Û
  • transport
    ¿î¹Ý
  • transcapillary transport
    ¸ð¼¼°ü¿î¹Ý
  • transmembrane transport
    ¸·¿î¹Ý
  • adoption phenomenon
    ä¿ëÇö»ó
  • aqueous-influx phenomenon
    ¹æ¼öÀ¯ÀÔÇö»ó
  • clasp-knife phenomenon
    Á¢´ÂÄ®Çö»ó
  • closing-in phenomenon
    Á¾°áÇö»ó
  • critical phenomenon
    ÀÓ°èÇö»ó
  • crowding phenomenon
    ¹ÐÁýÇö»ó
  • cytopathogenic phenomenon
    ¼¼Æ÷º¯¼ºÇö»ó
  • delay phenomenon
    Áö¿¬Çö»ó
  • discontinuity phenomenon
    ºÒ¿¬¼ÓÇö»ó
  • dissociative phenomenon
    ÇØ¸®Çö»ó
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Gunns pupillary phenomenon
    °Ç¾¾µ¿°øÇö»ó
  • Hirsts phenomenon
    Ç㽺Ʈ Çö»ó
  • Jack-in-the-box phenomenon
    µ¹¿¬½ÃÇö»ó
  • Kanagawa hemolysis phenomenon
    Ä«³ª°¡¿Í ¿ëÇ÷Çö»ó (º´¿ø¼º ºñºê¸®¿ÀÀÇ)
  • Kochs phenomenon
    ÄÚÈ£Çö»ó
  • Koebner phenomenon
    Äêºê³Ê Çö»ó
  • LE cell phenomenon
    LE¼¼Æ÷Çö»ó.
  • Lusts phenomenon
    ·¯½ºÆ® Çö»ó.
  • Mizuos phenomenon
    ¹ÌÁî¿ÀÇö»ó
  • Pel-Ebstein phenomenon
    Æç-¿¦½´Å¸ÀÎ Çö»ó
  • Pfeiffers phenomenon
    ÆÄÀÌÆÛ ¿ë±ÕÇö»ó (ÄÝ·¹¶ó±ÕÀÇ)
  • Pulfrich phenomenon
    Ç®ÇÁ¸®È÷Çö»ó
  • Raynaud s phenomenon
    ·¹À̳ëÇö»ó.
  • Raynauds phenomenon
    ·¹À̳ëµå Çö»ó
  • Riddoch phenomenon
    ¸®µµÅ©Çö»ó
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • medium, transport
    ¼ö¼Û¹èÁö
  • membrane transport
    ¼¼Æ÷¸·À» ÅëÇÑ À̵¿.
  • net transport
    ¼ø¿î¹Ý.
  • oxygen transport
    »ê¼Ò¿î¹Ý(¡­¿î¹Ý).
  • oxygen transport
    »ê¼Ò¿î¹Ý(¡­ê¡Úæ).
  • oxygen transport mechanism
    »ê¼Ò¿î¹Ý ±âÀü.
  • passive transport
    Çǵ¿Àû ¿î¹Ý(¡­ê¡Úæ).
  • piece, transport
    ¿î¹Ý¼ººÐ, ¼ö¼Û¼ººÐ
  • plasma membrane carnitine transport defect
  • sodium transport system
    ³ªÆ®·ý¿î¹Ý°è (¡­ê¡ÚæÍ§).
  • specimen transport
    °Ëü¼ö¼Û
  • supersonic transport
    ÃÊÀ½ÆÄ¼ö¼Û(¡­âÃáê).
  • symport= co- transport
    °øµ¿¿î¹Ý(ÍìÔÒê¡Úæ)
  • transcapillary transport
    ¸ð¼¼°ü¿î¹Ý (¡­ê¡Úæ)
  • transcapillary transport
    ¸ð¼¼°ü¿î¹Ý (¡­ê¡Úæ).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • homocellular transport
    µ¿Áú¼¼Æ÷ ¼ö¼Û(ÔÒòõá¬øàâÃáê)
  • hydrogen transport system
    ¼ö¼Ò ¼ö¼Û(â©áÈâÃáê) ½Ã½ºÅÛ
  • illicit transport
    ¹Ð¼ö¼Û(ÚËâÃáê)
  • intracellular transport
    ¼¼Æ÷³» ¼ö¼Û(á¬øàÒ®âÃáê)
  • mediated transport
    ¸Å°³¼ö¼Û(ØÚË¿âÃáê)
  • membrane transport
    ¸·À̵¿(دì¹ÔÑ)
  • nonmediated transport
    ºñ(Þª)¸Å°³ ¼ö¼Û(ØÚË¿âÃáê)
  • oxygen transport
    »ê¼Ò¿î¹Ý(ß«áÈê¡Úæ)
  • passive mediated transport
    ¼öµ¿ ¸Å°³¿î¹Ý(áôÔÑØÚË¿ê¡Úæ)
  • passive transport
    ¼öµ¿ ¼ö¼Û(áôÔÑâÃáê)
  • photosynthetic electron transport
    ±¤ÇÕ¼º ÀüÀÚ ¼ö¼Û(ï³í­âÃáê)
  • post-translational transport
    ¹ø¿ªÈÄ ¿î¹Ý(ê¡Úæ)
  • primary active transport
    ÀÏÂ÷ ´Éµ¿¼ö¼Û(ìéó­ÒöÔÑâÃáê)
  • secondary active transport
    ÀÌÂ÷ ´Éµ¿¼ö¼Û(ì£ó­ÒöÔÑâÃáê)
  • transcellular transport
    ¸·È¾´Ü ¼ö¼Û(دüôÓ¨âÃáê)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
VF   1) Ventricular Fibrillation
    ? Tx of Ventricular Fibrillation ...
B-G Bordet-Gengou [agar, bacillus, phenomenon]
CREST calcinosis, Raynaud phenomenon, esophageal involvement, sclerodactyly, and telangiectasia [syndrome]...
CRST calcinosis, Raynaud phenomenon, sclerodactyly, telangiectasia [syndrome]; corrected sinus recovery t...
PRP physiologic rest position; pityriasis rubra pilaris; platelet-rich plasma; polyribosyl ribitol phosp...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
HAChT High affinity choline transport
IFT Intraflagellar transport
MCT Mucociliary transport
NTF2 Nuclear transport factor 2
PST Phosphate Specific Transport
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • central pain phenomenon
    ÁßÃß¼º µ¿Åë Çö»ó
  • Chiristensen phenomenon
    Å©¸®½ºÅÙ¼¾ Çö»ó
    ÇϾÇÀÇ Àü¹æ¿îµ¿ ½Ã ´ëÇÕÇÏ´Â ±³ÇÕ¸é »çÀÌ¿¡ »ý±â´Â °£°Ý.
  • Christensen's phenomenon
    Å©¸®½ºÅÙ¼¾ Çö»ó
  • Class Switching phenomenon
    ºÐ·ù Àüȯ Çö»ó
    ÇϳªÀÇ B ¼¼Æ÷°¡ ±×¿¡ »óÀÀÇÒ ¼ö Àִ ƯÀÌ Ç׿ø¿¡ Á¢ÇÏ¿´À» ¶§ isoty
  • dawn phenomenon
    »õº® Çö»ó
    Á¦ 1Çü ´ç´¢º´ ȯÀÚÀÇ 75%¿¡¼­, ±×¸®°í ´Ù¼öÀÇ Á¦ 2Çü ´ç´¢º´ ȯÀÚ ¹× Á¤»óÀο¡¼­µµ ÀϾ´Ù. À̰ÍÀº ¿ÀÀü 5-8½Ã »çÀÌ¿¡ Àν¶¸°¿¡ ´ëÇÑ Á¶Á÷ÀÇ °¨¼ö¼ºÀÌ °¨¼ÒÇÏ¿© ÀϾ´Ù. ÃÖ±ÙÀÇ Áõ°Å´Â ÀÌ Çö»óÀÌ ¼ö¸é Áß¿¡ ¼ºÀå È£¸£¸ó ºÐºñÀÇ Áõ°¡¿¡ ÀÇÇÏ¿© À¯¹ßµÇ´Â °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ´Ù. »õº® Çö»óÀÌ ´Üµ¶À» ¹ß»ýÇϸé À̸¥ ¾ÆÄ§¿¡ °æµµÀÇ °íÇ÷´çÁõÀÌ ¿À³ª ¼Ò¸ð±â È¿°ú³ª °¨Åð Çö»óÀÌ µ¿¹ÝµÇ¸é °íÇ÷´çÁõÀº ½ÉÇØÁø´Ù.
  • dolls head phenomenon
    ÀÎÇü ¸Ó¸® Çö»ó, ÀÎÇü µÎ Çö»ó
  • flare phenomenon
    Àå°³ Çö»ó
  • Fowler phenomenon
    º¸Ãæ Çö»ó
  • iceberg phenomenon
    ºù»ê Çö»ó
  • jaw winking phenomenon
    ÅÎ-À®Å© Çö»ó
  • light absorption phenomenon
    ºû Èí¼ö Çö»ó
  • metallic phenomenon
    ±Ý¼Ó¼º Çö»ó
  • mucus extravasation phenomenon
    Á¡¾× À¯Ãâ Çö»ó
  • orbicularis phenomenon
    À±±Ù Çö»ó
  • phenomenon
    Çö»ó
    1. ¾î¶² ¡Èijª °´°üÀûÀÎ Áõ»ó. 2. ¾î¶² ÁÖ¸ñÇÒ¸¸ÇÑ »ç°Ç ¶Ç´Â »ç½Ç.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
channel transport <radiobiology> In inertial fusion research using light ion drivers, describes the use of current-carrying plasma channels (which are magnetically confined to the channel) to transport electron or ion beams between the ion diode and the fusion target. This allows the ion source to stand back from the target.
(09 Oct 1997)
reverse electron transport <chemistry> The energy-dependent movement of electrons against the thermodynamic gradient to form a strong reductant from a weaker electron donor.
(11 Jan 1998)
cholesterol ester transport proteins A protein that transports cholesterol esters from HDL to VLDL and LDL; a deficiency of this protein is associated with elevated HDL cholesterol.
(05 Mar 2000)
monosaccharide transport proteins Membrane transport proteins which bind glucose and sodium ions and enter the cell together. The sodium ions are then pumped out of the cell by a sodium potassium atpase. The rate and extent of the sugar transport depends on the sodium ion concentration. Inhibitors of the monosaccharide transport system are phlorizin, cytochalasin b, and inhibitors of the sodium potassium atpase system. Insulin increases the rate of monosaccharide transport across the membrane into the cell.
(12 Dec 1998)
cotranslational transport <cell biology> Process whereby a protein is moved across a membrane as it is being synthesised.
This process occurs during the translation of the message at membrane associated ribosomes in rough endoplasmic reticulum during the synthesis of secreted proteins in eukaryotic cells.
(18 Nov 1997)
coupled transport The linked, simultaneous transport of two substances across a cell membrane (or another intracellular membrane). If the two substances are moving in the same direction (both into the cell or both out of the cell) it is called symport. If the two substances are moving in opposite directions (one moves into the cell while the other moves out) it is called antiport.
(09 Oct 1997)
hydrogen transport The transfer of hydrogen from one metabolite (hydrogen donor) to another (hydrogen acceptor) through the action of an enzyme system; the donor is thus oxidised and the acceptor reduced.
(05 Mar 2000)
sperm transport Passive transport or active migration of spermatozoa from the testes through the male genital system as well as within the female genital system.
(12 Dec 1998)
nuclear transport <cell biology> Passage of molecules in and out of the nucleus, presumably via nuclear pores. Passage of proteins into the nucleus may depend on possession of a nuclear location sequence containing five consecutive positively charged residues PKKKRKV).
(18 Nov 1997)
nucleocytoplasmic transport <cell biology, molecular biology> Transport of molecules from the nucleus to the cytoplasm.
(18 Nov 1997)
iodide transport defect See: familial goiter.
(05 Mar 2000)
ion transport The movement of ions across energy-transducing cell membranes. Transport can be active or passive. Passive ion transport (facilitated diffusion) derives its energy from the concentration gradient of the ion itself and allows the transport of a single solute in one direction (uniport). Active ion transport is usually coupled to an energy-yielding chemical or photochemical reaction such as ATP hydrolysis. This form of primary active transport is called an ion pump. Secondary active transport utilises the voltage and ion gradients produced by the primary transport to drive the cotransport of other ions or molecules. These may be transported in the same (symport) or opposite (antiport) direction.
(12 Dec 1998)
orthograde transport Axonal transport from the cell body of the neuron towards the synaptic terminal. Opposite of retrograde transport and probably dependent on a different mechanochemical protein (almost definitely kinesin) interacting with microtubules.
(18 Nov 1997)
ovum transport Transport of the ovum or zygote from the site of ovulation to the site of implantation.
(12 Dec 1998)
electron transport The transport of electrons through a number of electron carriers in a set sequence.
(09 Oct 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á